CorMedix, Inc. (CRMD)
7.75
-0.14
(-1.77%)
USD |
NASDAQ |
Sep 15, 16:00
7.75
0.00 (0.00%)
After-Hours: 20:00
CorMedix Enterprise Value : 500.59M for Sept. 14, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 14, 2026 | 500.59M |
| September 11, 2026 | 495.55M |
| September 10, 2026 | 506.03M |
| September 09, 2026 | 519.23M |
| September 08, 2026 | 523.12M |
| September 04, 2026 | 542.53M |
| September 03, 2026 | 545.64M |
| September 02, 2026 | 556.51M |
| September 01, 2026 | 538.65M |
| August 31, 2026 | 529.33M |
| August 28, 2026 | 532.44M |
| August 27, 2026 | 533.21M |
| August 26, 2026 | 539.43M |
| August 25, 2026 | 552.63M |
| August 24, 2026 | 530.88M |
| August 21, 2026 | 524.67M |
| August 20, 2026 | 527.00M |
| August 19, 2026 | 549.52M |
| August 18, 2026 | 522.34M |
| August 17, 2026 | 483.51M |
| August 14, 2026 | 473.41M |
| August 13, 2026 | 520.01M |
| August 12, 2026 | 439.24M |
| August 11, 2026 | 454.77M |
| August 10, 2026 | 472.63M |
| Date | Value |
|---|---|
| August 07, 2026 | 465.64M |
| August 06, 2026 | 471.08M |
| August 05, 2026 | 463.31M |
| August 04, 2026 | 471.86M |
| August 03, 2026 | 474.19M |
| July 31, 2026 | 472.63M |
| July 30, 2026 | 469.53M |
| July 29, 2026 | 446.23M |
| July 28, 2026 | 458.65M |
| July 27, 2026 | 478.07M |
| July 24, 2026 | 499.04M |
| July 23, 2026 | 513.02M |
| July 22, 2026 | 504.48M |
| July 21, 2026 | 523.89M |
| July 20, 2026 | 492.05M |
| July 17, 2026 | 541.76M |
| July 16, 2026 | 531.66M |
| July 15, 2026 | 541.76M |
| July 14, 2026 | 530.11M |
| July 13, 2026 | 533.99M |
| July 10, 2026 | 540.20M |
| July 09, 2026 | 561.17M |
| July 08, 2026 | 573.60M |
| July 07, 2026 | 576.71M |
| July 06, 2026 | 570.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Innoviva, Inc. | 1.209B |
| Zevra Therapeutics, Inc. | 495.00M |
| Filana Therapeutics, Inc. | -47.96M |
| Eloxx Pharmaceuticals, Inc. | 3.827M |
| Cannabis Global, Inc. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 25.99M |
| Revenue (Quarterly) | 101.93M |
| Total Expenses (Quarterly) | 75.94M |
| EPS Diluted (Quarterly) | 0.281 |
| Gross Profit Margin (Quarterly) | 75.66% |
| Profit Margin (Quarterly) | 25.50% |
| Earnings Yield | 27.16% |
| Operating Earnings Yield | 30.64% |
| Normalized Earnings Yield | 28.41 |